Modulation of Covid‐19 cytokine storm by tocilizumab
Abstract Coronavirus disease 2019 (Covid‐19) is the illness caused by severe acute
respiratory syndrome coronavirus 2, first identified in Wuhan, China at the end of 2019. On …
respiratory syndrome coronavirus 2, first identified in Wuhan, China at the end of 2019. On …
[PDF][PDF] The effect of tocilizumab on severe COVID-19 infection: Review of current evidence
The COVID-19 outbreak that spread in December 2019 has caused the death of millions of
people in a short time. Many studies published recently have shown that many cytokines …
people in a short time. Many studies published recently have shown that many cytokines …
Systematic review on treatment trials of tocilizumab: a repurposing drug against COVID-19
S Banerjee, AK Mahapatra - Reviews on Recent Clinical Trials, 2021 - ingentaconnect.com
Background: Coronavirus disease (COVID-19) caused by Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2) has become a global issue today. There exists an …
Syndrome Coronavirus 2 (SARS-CoV-2) has become a global issue today. There exists an …
[HTML][HTML] Tocilizumab and COVID-19: timing of administration and efficacy
E Abidi, WS El Nekidy, E Alefishat, N Rahman… - Frontiers in …, 2022 - frontiersin.org
Elevated concentrations of interleukin-6 have been demonstrated to be an important key
factor in COVID-19 host immune impairment. It represents an important prognostic factor of …
factor in COVID-19 host immune impairment. It represents an important prognostic factor of …
[HTML][HTML] Rational use of tocilizumab in the treatment of novel coronavirus pneumonia
S Zhang, L Li, A Shen, Y Chen, Z Qi - Clinical drug investigation, 2020 - Springer
Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in
Wuhan, China and spread rapidly. Recent studies have found that⁓ 15.7% of patients …
Wuhan, China and spread rapidly. Recent studies have found that⁓ 15.7% of patients …
[HTML][HTML] Why tocilizumab could be an effective treatment for severe COVID-19?
B Fu, X Xu, H Wei - Journal of translational medicine, 2020 - Springer
A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was
identified in December 2019 (COVID-19), spread rapidly and has become a world-wide …
identified in December 2019 (COVID-19), spread rapidly and has become a world-wide …
[HTML][HTML] Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients
J Zeng, MH Xie, J Yang, SW Chao… - World Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
BACKGROUND The main pathophysiological basis of coronavirus disease 2019 (COVID-
19) causing respiratory failure is a cytokine storm and interleukin-6 (IL-6) is an important …
19) causing respiratory failure is a cytokine storm and interleukin-6 (IL-6) is an important …
Tocilizumab for the treatment of severe coronavirus disease 2019
Abstract Tocilizumab, an interleukin‐6 inhibitor, may ameliorate the inflammatory
manifestations associated with severe coronavirus disease 2019 (COVID‐19) and thus …
manifestations associated with severe coronavirus disease 2019 (COVID‐19) and thus …
[HTML][HTML] Tocilizumab as treatment for COVID-19: a systematic review and meta-analysis
F Petrelli, S Cherri, M Ghidini, G Perego… - World Journal of …, 2021 - ncbi.nlm.nih.gov
BACKGROUND The majority of patients with coronavirus disease 2019 (COVID-19) have
good prognoses, but some develop a critical illness that can lead to death. Evidence shows …
good prognoses, but some develop a critical illness that can lead to death. Evidence shows …
[HTML][HTML] Repurposed tocilizumab in patients with severe COVID-19
J Tian, M Zhang, M Jin, F Zhang, Q Chu… - The Journal of …, 2021 - journals.aai.org
The coronavirus disease 2019 (COVID-19) has caused a global pandemic, resulting in
considerable morbidity and mortality. Tocilizumab, an inhibitor of IL-6, has been widely …
considerable morbidity and mortality. Tocilizumab, an inhibitor of IL-6, has been widely …